Brian Petullo, MD, FHM
Article
SGLT-2 Inhibitors’ Increased Risk of PAD-Related Surgical Events Compared to DPP-4 Inhibitors’ Risk When Used as Add-On Therapy in Diabetes
October 1, 2025
CLINICAL QUESTION: Do sodium-glucose cotransporter-2 (SGLT-2) inhibitors, as add-on therapy for diabetes, increase the risk of amputations, stent placement, or revascularization surgeries compared...